Home › Funds › Octagon Capital Advisors LP › FTH
Octagon Capital Advisors LP position in FTH
FAETH THERAPEUTICS INC
Octagon Capital Advisors LP reported holding 100,000 shares of FTH (FAETH THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 0.40% of its reported portfolio and ranking #23 among its reported holdings. Octagon Capital Advisors LP has disclosed FTH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Octagon Capital Advisors LP's FTH position evolved
Octagon Capital Advisors LP first disclosed a stake in FTH in Q2 2026 at 361,010 shares (US$9.0M). Across 2 filings, Octagon Capital Advisors LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 100,000 shares valued at US$3.0M — a reduction of -261,010 shares quarter over quarter.. Notable position changes include a 72% trim in Q3 2026 (shares fell 69% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 361.01K | $9.03M | New |
| Q3 2026 | 100.00K | $2.97M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About FTH and 13F data
FTH (FAETH THERAPEUTICS INC) is a company whose sector is not yet classified in our data. 78 other funds we track also report a position in FTH — the largest reported positions include MONTANOVA CAPITAL, LLC (US$68.7M), Avoro Capital Advisors LLC (US$41.9M), Cormorant Asset Management, LP (US$30.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding FTH
- MONTANOVA CAPITAL, LLC 2.31M sh · $68.72M · Q3 2026
- Avoro Capital Advisors LLC 1.41M sh · $41.93M · Q3 2026
- Cormorant Asset Management, LP 1.03M sh · $30.58M · Q3 2026
- Trails Edge Capital Partners, LP 941.69K sh · $28.01M · Q3 2026
- Caligan Partners LP 890.21K sh · $26.47M · Q3 2026
- Vivo Capital, LLC 844.58K sh · $25.12M · Q3 2026
- BAKER BROS. ADVISORS LP 803.42K sh · $23.89M · Q3 2026
- Fairmount Funds Management LLC 722.02K sh · $21.47M · Q3 2026
- B Group, Inc. 610.17K sh · $18.15M · Q3 2026
- STEMPOINT CAPITAL LP 404.92K sh · $12.04M · Q3 2026
- Ikarian Capital, LLC 199.69K sh · $5.94M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 124.10K sh · $3.69M · Q3 2026
More on Octagon Capital Advisors LP
FAQ
How long has Octagon Capital Advisors LP held FTH?
Octagon Capital Advisors LP has disclosed FTH holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Octagon Capital Advisors LP's current position in FTH?
As of Q3 2026, Octagon Capital Advisors LP holds 100.00K shares of FTH (FAETH THERAPEUTICS INC), valued at $2.97M, representing 0.40% of its reported portfolio and ranking #23.
Has Octagon Capital Advisors LP been buying or selling FTH?
In the latest 13F filing (Q3 2026), Octagon Capital Advisors LP reduced its position in FTH.
Which other funds hold FTH?
Other major institutional holders of FTH include MONTANOVA CAPITAL, LLC, Avoro Capital Advisors LLC, Cormorant Asset Management, LP, among 78 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.